Similar articles

• The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.

  Yamazaki M, Fukutomi O, Kondo N, Kato Z, Nakashima Y, Shinoda S, Agata H, Kondo T, Imaeda N, Orii T. Yamazaki M, et al. Int J Clin Pharmacol Ther. 1994 Nov;32(11):625-31. Int J Clin Pharmacol Ther. 1994. PMID: 7874380
• A comparison of absorption rate models in the prediction of steady-state plasma concentrations during oral theophylline administration.

  Paterson CM, Hudson SA, Jefferson GC. Paterson CM, et al. J Clin Pharm Ther. 1987 Feb;12(1):39-46. J Clin Pharm Ther. 1987. PMID: 3449562
• Prediction of steady-state serum theophylline concentration in children by first-order and zero-order absorption models.

  Kato Z, Fukutomi O, Yamazaki M, Kondo N, Imaeda N, Orii T. Kato Z, et al. Int J Clin Pharmacol Ther. 1994 May;32(5):231-4. Int J Clin Pharmacol Ther. 1994. PMID: 7921516
• Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.

  Takagi K, Hasegawa T, Ogura Y, Yamaki K, Suzuki R, Satake T, Imaeda N, Mizukami Y. Takagi K, et al. Int J Clin Pharmacol Ther Toxicol. 1987 Oct;25(10):530-5. Int J Clin Pharmacol Ther Toxicol. 1987. PMID: 3429057
• Transdermal delivery and the premature neonate.

  Barrett DA, Rutter N. Barrett DA, et al. Crit Rev Ther Drug Carrier Syst. 1994;11(1):1-30. Crit Rev Ther Drug Carrier Syst. 1994. PMID: 7704917 Review.